Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Strengthening capabilities in Peptide Therapeutics and CDMO services
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Subscribe To Our Newsletter & Stay Updated
